Vaccine and Treatment Evaluation Units (VTEU)

The National Institutes of Health established the Vaccine and Treatment Evaluation Units Master IDIQ on September 9, 2013, with a shared ceiling of $951.7 million, but ordering closed on September 15, 2023, placing this vehicle outside the active procurement window. The vehicle is no longer accepting new task orders.

Over its operational life, the IDIQ issued 213 task orders with a combined potential value of $385 million, of which $232.8 million (60%) has been obligated. Activity declined sharply in recent years: the vehicle issued 41 orders in 2016, but only one order in 2020, with no awards after February 4, 2020. The most recent task order portfolio reflects work awarded through mid-2020, with many completions and de-obligations occurring in 2022 through 2025 as remaining funded work closes out.

All 213 task orders carry no set-aside designation, operating on a fully unrestricted competitive basis. Task orders fund Phase 0 through Phase IV clinical trials, clinical trials for devices and diagnostics, clinical studies, sample collection, sample analysis, surveillance, and epidemiology studies in infectious diseases across domestic and international populations.

Five academic medical centers dominate the award base: University of Maryland, Baltimore holds 30 orders valued at $78.6 million; Emory University holds 28 orders valued at $72.8 million; Duke University holds 27 orders valued at $63.6 million; Children's Hospital Medical Center holds 22 orders valued at $56.5 million; and Baylor College of Medicine holds 20 orders valued at $27.5 million. These five primes capture 78% of the vehicle's combined potential value. Individual task-order ceilings range from under $100 thousand to approximately $12 million, with most orders priced on a cost-no-fee basis.

The National Institute of Allergy and Infectious Diseases funds 208 of the 213 orders, accounting for $384.2 million of the $385 million combined potential value. Three additional NIH components—NIAID DEA OA Acquisitions, National Heart Lung and Blood Institute, and Center for Information Technology—collectively fund only five orders totaling approximately $877 thousand.

Because the ordering period closed nearly three years ago and no new task orders have been issued since February 2020, this vehicle presents no opportunity for pursuit of new work.

Support the conduct of clinical studies and clinical trials related to infectious diseases in a variety of domestic and international populations. Examples of studies that will be conducted include Phase 0 through Phase IV clinical trials, clinical trials for devices and diagnostics, clinical studies, sample collection, sample analysis, surveillance, and epidemiology studies.